中低收入国家四价流感疫苗的成本效益、可负担性与可及性
本文评论de Boer等受WHO委托的动态模型研究,讨论中低收入国家用四价流感疫苗(QIV)替代三价灭活疫苗(TIV)的决策考量。基于该研究数据推断,在南非和越南替代将使流感疫苗接种预算增加25-29%,而假定10%有症状罹患率时流感相关健康影响仅额外降低7-8%。作者认为除非不确定性、不实用性和成本增加得到解决,TIV对许多中低收入国家仍是更有吸引力的选择。
要点
- 南非和越南用QIV替代TIV将使季节性流感疫苗接种预算增加25-29%。
- 假定10%有症状罹患率时,替代带来的流感相关健康影响额外降低仅7-8%。
- 作者认为除非QIV相关不确定性、不实用性和成本增加得到解决,TIV对许多中低收入国家仍更有吸引力。
核心结论
- 除非当前与QIV相关的不确定性、不实用性和成本增加得到解决,TIV对许多中低收入国家可能仍是更有吸引力的选择。
- 每个国家应基于本国疾病负担和成本数据建立情境特异的决策流程,以判断健康获益是否超过转向QIV的额外成本。
研究设计与样本
- 本文为评论文章,讨论de Boer等(2008)受WHO委托的动态模型研究及中低收入国家用QIV替代TIV的决策考量。
主要发现
- 从de Boer等论文数据可推断,在南非和越南用QIV替代TIV将使季节性流感疫苗接种预算增加25-29%。
- 假定10%有症状罹患率时,上述替代带来的流感相关健康影响额外降低仅7-8%。
- 作者认为中低收入国家的国家卫生预算考量可能使决策者选择其他以约相当于每年TIV免疫接种费用四分之一的预算获得更高健康影响的投资。
临床怎么用
- 作者认为用TIV为更多人群尤其是高风险组接种,在中低收入国家可能不仅更具性价比,还能带来更好的健康结局。
- 作者认为具备本地流感疫苗生产能力的国家应在季节性流感疫苗采购流程中纳入TIV与QIV利弊分析,以确保本地生产的可行性和可持续性。
- 作者认为每个国家应基于本国疾病负担和成本数据建立情境特异的决策流程。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In high-income countries, there is an increased tendency to replace inactivated seasonal trivalent influenza (TIV) vaccines with quadrivalent (QIV) vaccines as these are considered to give a greater public health benefit. In addition, several recent studies from the USA and Europe indicate that replacement with QIV might also be cost-effective; however, the situation in low- and middle-income countries (LMIC) is less clear as few studies have investigated this aspect. The paper by de Boer et al. (2008) describes a dynamic modelling study commissioned by WHO that suggests that in LMICs, under certain conditions, QIV might also be more cost-effective than TIV. In this commentary, we discuss some important aspects that policymakers in LMICs might wish to take into account when considering replacing TIV by QIV. Indeed, from the data presented in the paper by de Boer et al. it can be inferred that replacing QIV for TIV would mean a 25-29% budget increase for seasonal influenza vaccination in South Africa and Vietnam, resulting in an incremental influenza-related health impact reduction of only 7-8% when a 10% symptomatic attack rate is assumed. We argue that national health budget considerations in LMIC might lead decision-makers to choose other investments with higher health impact for a budget equivalent to roughly a quarter of the yearly TIV immunization costs. In addition to an increased annual cost that would be associated with a decision to replace TIV with QIV, there would be an increased pressure on manufacturers to produce QIV in time for the influenza season requiring manufacturers to produce some components of the seasonal vaccine at risk prior to the WHO recommendations for influenza vaccines. Unless the current uncertainties, impracticalities and increased costs associated with QIVs are resolved, TIVs are likely to remain the more attractive option for many LMICs. Each country should establish its context-specific process for decision-making based on national data on disease burden and costs in order to determine whether the health gains out-weigh the additional cost of moving to QIV. For example, immunizing more people in the population, especially those in higher risk groups, with TIV might not only provide better value for money but also deliver better health outcomes in LMICs. Countries with local influenza vaccine manufacturing capacity should include in their seasonal influenza vaccine procurement process an analysis of the pros- and cons- of TIV versus QIV, to ensure both feasibility and sustainability of local manufacturing.
引用
- Hendriks J, Hutubessy RCW, Grohmann G, et al. Quadrivalent influenza vaccines in low and middle income countries: Cost-effectiveness, affordability and availability. Vaccine. 2018. PMID: 29866617. doi:10.1016/j.vaccine.2018.05.099
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。